International ExpansionOCX initiated shipping its GraftAssure RUO kidney kit to transplant centers and research universities in the U.S., Asia, and Europe.
Market PotentialThe transplant rejection diagnostics market is large and growing rapidly and OCX's GraftAssure and VitaGraft tests can capture significant market share and serve as strong growth drivers.
Strategic PartnershipsOCX has partnered with Bio-Rad Laboratories to commercialize its GraftAssure and VitaGraft tests and BIO has taken a ~9% stake in OCX.